Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Kimberly-Clark’s second quarter 2026 results demonstrate ongoing resilience amidst a challenging global environment.</li><li>The company reported its tenth consecutive quarter of positive volume plus mix growth and maintained global weighted share, supported by strong gross productivity gains.</li><li>Despite facing headwinds, including consumer pressure, moderating category growth, and disruptive events, the company achieved solid operating profit and earnings per share that exceeded internal expectations, largely due to a favorable $45 million tariff refund and successful productivity improvements of 6.4%.</li></ul>

Kimberly-Clark’s second quarter 2026 results demonstrate ongoing resilience amidst a challenging global environment.The company reported its tenth consecutive quarter of positive volume plus mix growth and maintained global weighted share, supported by strong gross productivity gains.Despite facing headwinds, including consumer pressure, moderating category growth, and disruptive events, the company achieved solid operating profit and earnings per share that exceeded internal expectations, largely due to a favorable $45 million tariff refund and successful productivity improvements of 6.4%.

Kimberly-Clark’s Kenvue Acquisition: Could It Reshape The Consumer Health Giant?

US-EU Index Rebalances / Quantitative Researcher

Dimitris Ioannidis

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Index Rebalance

Alnylam Pharmaceuticals / Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US)</a>, <a href="https://www.smartkarma.com/entities/monolithic-power-systems-inc" target="_blank" data-smartkarma-citation="entities:2088:1" rel="noopener">Monolithic Power Systems (MPWR US)</a> and <a href="https://www.smartkarma.com/entities/seagate-technology-holdings-pl" target="_blank" data-smartkarma-citation="entities:9129:1" rel="noopener">Seagate Technology Holdings (STX US)</a> are the top 3 addition candidates with ALNY at the top.</li>
<li>
<a href="https://www.smartkarma.com/entities/globalfoundries-inc" target="_blank" data-smartkarma-citation="entities:34513:1" rel="noopener">GLOBALFOUNDRIES (GFS US)</a>, <a href="https://www.smartkarma.com/entities/cdw-corp-de" target="_blank" data-smartkarma-citation="entities:2244:1" rel="noopener">CDW Corp (CDW US)</a> and <a href="https://www.smartkarma.com/entities/biogen-inc" target="_blank" data-smartkarma-citation="entities:972:1" rel="noopener">Biogen (BIIB US)</a> are the top 3 deletion candidates with GFS at the bottom.</li>
<li>Versant (VSNT) and Solstice Advanced Materials (SOLS) are estimated to be deleted following completion of their spinoffs with the earliest one expected on 30 October 2025.</li>
</ul>



Alnylam Pharmaceuticals (ALNY US), Monolithic Power Systems (MPWR US) and Seagate Technology Holdings (STX US) are the top 3 addition candidates with ALNY at the top.

GLOBALFOUNDRIES (GFS US), CDW Corp (CDW US) and Biogen (BIIB US) are the top 3 deletion candidates with GFS at the bottom.
Versant (VSNT) and Solstice Advanced Materials (SOLS) are estimated to be deleted following completion of their spinoffs with the earliest one expected on 30 October 2025.


Nasdaq100 Dec2025 Forecast (Part 2): ALNY at the Top; GFS at the Bottom; Spinoffs Pending

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>Bloomberg <a href="https://www.bloomberg.com/news/articles/2023-11-10/asia-pulp-paper-is-said-to-bid-for-stake-in-tissue-maker-vinda#xj4y7vzkg" target="_blank" rel="noopener">reported</a> Asia Pulp &amp; Paper is the latest party to have expressed interest in acquiring <a href="https://www.smartkarma.com/entities/essity-ab" target="_blank" data-smartkarma-citation="entities:28203:1" rel="noopener">Essity (ESSITYB SS)</a>’s controlling <a href="https://www.smartkarma.com/entities/vinda-international-holdings-limited" target="_blank" data-smartkarma-citation="entities:475:1" rel="noopener">Vinda International (3331 HK)</a> stake at more than HK$20 per share.</li>
<li>Vinda has three substantial shareholders. We think the most likely structure is a bidder acquiring Essity’s stake, which would trigger a mandatory general offer.</li>
<li>Vinda's recent update points to improving growth and margins. Peers and historical multiples imply a fair price range of HK$21-26 per share, a 7-32% premium to the last close.</li>
</ul>


Bloomberg reported Asia Pulp &amp; Paper is the latest party to have expressed interest in acquiring Essity (ESSITYB SS)’s controlling Vinda International (3331 HK) stake at more than HK$20 per share.
Vinda has three substantial shareholders. We think the most likely structure is a bidder acquiring Essity’s stake, which would trigger a mandatory general offer.
Vinda's recent update points to improving growth and margins. Peers and historical multiples imply a fair price range of HK$21-26 per share, a 7-32% premium to the last close.


Vinda International (3331 HK): Essity’s Stake Attracts More Potential Bidders

<ul><li>Kimberly-Clark’s first quarter performance reflects continued progress in its strategic transformation and demonstrates solid organic sales growth driven by innovation, particularly in its key focus areas of Baby Care, Women’s Health, and Active Aging.</li><li>The company achieved a 3% increase in volume plus mix growth—marking a ninth or tenth consecutive quarter of positive growth—supported by differentiated, science-backed innovations and a disciplined promotional approach.</li><li>Notably, promotion levels in North America remained below pre-COVID category levels, with promotional activities selectively used to drive trial for new products like the Snug & Dry diaper innovation.</li></ul>

Kimberly-Clark’s first quarter performance reflects continued progress in its strategic transformation and demonstrates solid organic sales growth driven by innovation, particularly in its key focus areas of Baby Care, Women’s Health, and Active Aging.The company achieved a 3% increase in volume plus mix growth—marking a ninth or tenth consecutive quarter of positive growth—supported by differentiated, science-backed innovations and a disciplined promotional approach.Notably, promotion levels in North America remained below pre-COVID category levels, with promotional activities selectively used to drive trial for new products like the Snug & Dry diaper innovation.

Kimberly-Clark: 6% Productivity Gains May Not Be Enough For Back-Half Cost Pressure!

<ul><li>Kimberly-Clark's recent earnings call for Q4 2025 delivers a comprehensive perspective on its current performance and future outlook.</li><li>The company's leadership highlighted significant progress under its "Powering Care" initiative, emphasizing the strategic enhancements and robust execution over the past years despite market challenges.</li><li>From an investment perspective, Kimberly-Clark demonstrates strengths in volume-plus-mix growth, supported by consistent share gains and industry-leading productivity.</li></ul>

Kimberly-Clark's recent earnings call for Q4 2025 delivers a comprehensive perspective on its current performance and future outlook.The company's leadership highlighted significant progress under its "Powering Care" initiative, emphasizing the strategic enhancements and robust execution over the past years despite market challenges.From an investment perspective, Kimberly-Clark demonstrates strengths in volume-plus-mix growth, supported by consistent share gains and industry-leading productivity.

Kimberly-Clark’s Channel Optimization Strategy—and Why It Matters More Than Pricing!

United States

Kimberly-Clark Corporation is a global health and hygiene company that manufactures and provides consumer products. The Company's products include diapers, tissues, paper towels, incontinence care products, surgical gowns, and disposable face masks.  Kimberly-Clark's products are sold in countries around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kimberly Clark (KMB US)

Kimberly-Clark’s Kenvue Acquisition: Could It Reshape The Consumer Health Giant?

Kimberly-Clark’s second quarter 2026 results demonstrate ongoing resilience amidst a challenging global environment. The company reported its...

Baptista Research

Nasdaq100 Dec2025 Forecast (Part 2): ALNY at the Top; GFS at the Bottom; Spinoffs Pending

SOLS was deleted from the index at the close of 6 Nov following Honeywell’s spinoff. VSNT is still expected to be removed but Comcast’s spinoff has...

Dimitris Ioannidis

Vinda International (3331 HK): Essity’s Stake Attracts More Potential Bidders

Vinda’s improving performance has supported the increasing list of potential bidders. The most likely bid structure is the acquisition of Essity’s...

Arun George

Kimberly-Clark: 6% Productivity Gains May Not Be Enough For Back-Half Cost Pressure!

Kimberly-Clark’s first quarter performance reflects continued progress in its strategic transformation and demonstrates solid organic sales growth...

Baptista Research

Kimberly-Clark’s Channel Optimization Strategy—and Why It Matters More Than Pricing!

Kimberly-Clark's recent earnings call for Q4 2025 delivers a comprehensive perspective on its current performance and future outlook. The...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)